Life Sciences

Expenditures for retail prescriptions have been roughly stable for the past two decades as a share of total U.S. health-care expenditures. Instead of applying broad price controls, policymakers should promote affordability and mitigate out-of-pocket costs for individuals.
Life Sciences
Check a box to narrow search for individual content items that cover numerous issues.
March 29, 2022
ITIF hosted a panel discussion with leading experts on innovation policy, technology transfer, and business, who spoke to the practical implications of exercising federal “march-in” rights and why it would be a grave and ill-timed mistake for the U.S. health, competitiveness, and research landscape.
March 16, 2022
Expenditures for retail prescriptions have been roughly stable for the past two decades as a share of total U.S. health-care expenditures. Instead of applying broad price controls, policymakers should promote affordability and mitigate out-of-pocket costs for individuals.
March 15, 2022
America’s world-leading life-sciences innovation system is a product of myriad policies, but one that is all too often overlooked is the Bayh-Dole Act, which gives IP rights to universities that produce innovation with federally funded R&D.
February 21, 2022
President Biden recently announced the administration is reigniting its “Cancer Moonshot” initiative, but its drug-pricing agenda presents a problem.
January 24, 2022
By utilizing new data on medical research output and administrative death records, a recent study from the National Bureau of Economic Research (NBER) produces estimates on the causal link between biomedical research and health outcomes.
November 22, 2021
Capitol Hill is awash in proposals to stem allegedly out-of-control drug prices, but in their zealousness to rein in drug prices, policymakers risk imperiling drug innovation to the detriment of patients and the economy. The better way to produce more medical cures at lower cost over the long haul will be to double down on innovation, not deter it.
November 22, 2021
America has lost 70 percent of its semiconductor manufacturing capacity over the last three decades. That serves as a harsh lesson for policymakers: Failing to maintain a supportive policy environment could set up other high-tech industries to falter, too.
November 15, 2021
The United States is the leader in life sciences innovation, but that has not always been the case. As global competition intensifies, it needs to continue spurring investment in R&D to stay on top. Rob and Jackie sat down with Stephen Ezell, vice president of global innovation policy at ITIF, to discuss the history of U.S. life sciences innovation and break down R&D costs versus the market prices of innovative biopharmaceuticals.
October 18, 2021
When factoring in the high value of positive externalities created by new drugs, consumer prices become a small price to pay for the wealth of private and public benefits that biopharmaceutical innovations create.

Pages